PBLS (Parabilis Medicines) Ending Cash Position: $30.57 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.43
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines Ending Cash Position?

Parabilis Medicines PBLS -4.21% 10 Ending Cash Position is $30.57 Mil as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Parabilis Medicines's Ending Cash Position for the quarter that ended in Dec. 2025 was $30.57 Mil.

Parabilis Medicines's quarterly Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($50.14 Mil) but then declined from Dec. 2024 ($50.14 Mil) to Dec. 2025 ($30.57 Mil).

Parabilis Medicines's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($50.14 Mil) but then declined from Dec. 2024 ($50.14 Mil) to Dec. 2025 ($30.57 Mil).

Parabilis Medicines Ending Cash Position Related Terms

Parabilis Medicines Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Ending Cash Position Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Ending Cash Position
50.14 30.57

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Ending Cash Position 50.14 30.57
PBLS
10GF Score
Parabilis Medicines Inc PBLS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Parabilis Medicines's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=50.139+-19.573
=30.57

Parabilis Medicines's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=50.139+-19.573
=30.57

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $30.57 Mil mean?
Parabilis Medicines (PBLS) has a Ending Cash Position of $30.57 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Parabilis Medicines and its competitors.
Is Parabilis Medicines' Ending Cash Position too high?
Parabilis Medicines' current Ending Cash Position is $30.57 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Ending Cash Position compare to IDYA and ELVN?
Parabilis Medicines' Ending Cash Position of $30.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current Ending Cash Position is $30.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Ending Cash Position of $30.57 Mil. The current Ending Cash Position is $30.57 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Ending Cash Position is $30.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.43
Price